FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

| OMB APPROVAL | | | | | | | | | |
|--------------------------|-----------|--|--|--|--|--|--|--|--|
| OMB Number: | 3235-0287 | | | | | | | | |
| Estimated average burden | | | | | | | | | |
| hours per respons | e: 0.5 | | | | | | | | |

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| Name and Address of Reporting Person* York Charles N II | | | | | | 2. Issuer Name and Ticker or Trading Symbol <u>Day One Biopharmaceuticals, Inc.</u> [DAWN] | | | | | | | | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner | | | | | |
|--|---|--|--|---------|---|--|---|------------------|---|---------------|--|---|---|---|---|----------------|--|--|--|
| (Last) (First) (Middle) 2000 SIERRA POINT PARKWAY, SUITE 501 | | | | | | 3. Date of Earliest Transaction (Month/Day/Year) 05/15/2024 | | | | | | | | X Officer (give title Other (specify below) COO, CFO AND SECRETARY | | | | | |
| 2000 SIERRA FOINT FARK WAT, SUITE 301 | | | | | | | If Amendment, Date of Original Filed (Month/Day/Year) | | | | | | | 6. Individual or Joint/Group Filing (Check Applicable Line) | | | | | |
| (Street) BRISBA | NE C | CA 94005 | | | | | | | | | | | | X Form filed by One Reporting Person Form filed by More than One Reporting Person | | | | | |
| (City) | City) (State) (Zip) | | | | | Rule 10b5-1(c) Transaction Indication | | | | | | | | | | | | | |
| | | | | | | Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10. | | | | | | | | | | | | d to | |
| | | Tab | le I - N | on-Deri | ative | Sec | curiti | ies Ac | quire | d, Di | sposed o | of, or Be | neficia | Ily Owne | d | | | | |
| 1. Title of Security (Instr. 3) 2. Transact Date (Month/Day | | | | | | Execution Date, | | | | | es Acquired (A) or Of (D) (Instr. 3, 4 an | | 5. Amount of Securities Beneficially Owned Following Reported | | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | | 7. Nature of Indirect Beneficial Ownership | | |
| | | | | | | | | v | Amount | (A) or (D) | Price | Transac | Transaction(s) (Instr. 3 and 4) | | | (Instr. 4) | | | |
| Common | 05/15/ | 2024 | 024 | | | | | 1,375 | A | (1) | 218,668 | | D | | | | | | |
| Common | 2024 | 024 | | | | | 2,250 | A | (1) | 220,918 | | D | | | | | | | |
| Common Stock 05/15/2 | | | | | | 024 | | | M | | 6,625 | A | (1) | (1) 227,543 | | | D | | |
| Common Stock 05/16/20 | | | | | | 024 | | S ⁽²⁾ | | 2,675 | D | \$16.07 | 87 22 | 4,868 | D | | | | |
| | | T | able II | | | | | | | | posed of converti | | | y Owned | | | | | |
| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Dee Execution if any (Month/I | med | 4. Transaction Code (Instr. 8) | | of | | 6. Date Exerci Expiration Dat (Month/Day/Ye | | isable and | 7. Title and Amount of Securities Underlying Derivative Securit (Instr. 3 and 4) | | 8. Price of Derivative Security (Instr. 5) | 9. Number derivative Securities Beneficial Owned Following Reported Transactic (Instr. 4) | e s illy | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) | |
| | | | | | Code | v | (A) | (D) | Date Exercis | able | Expiration Date | Title | Amount or Number of Shares | | | | | | |
| Restricted Stock Unit (RSU) | (1) | 05/15/2024 | | | М | | | 1,375 | (3) | | (3) | Common Stock | 1,375 | \$0 | 8,250 | | D | | |
| Restricted Stock Unit (RSU) | (1) | 05/15/2024 | | | М | | | 2,250 | (3) | | (3) | Common Stock | 2,250 | \$0 | 22,500 |) | D | | |
| Restricted Stock Unit (RSU) | (1) | 05/15/2024 | | | M | | | 6,625 | (3) | | (3) | Common Stock | 6,625 | \$0 | 92,750 |) | D | | |

Explanation of Responses:

- 1. Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration.
- 2. The sale of shares is for the sole purpose of covering the Reporting Person's tax liability with respect to the settlement of RSUs.
- 3. The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

/s/ Charles N. York II

05/17/2024

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.